Answers are grounded in this paper and cite their sources.
The in vitro activities of tigecycline and selected antimicrobials were evaluated against a variety of multiple-drug-resistant clinical isolates, including extended-spectrum beta-lactamase- and/or metallo-beta-lactamase-producing gram-negative strains, colistin-resistant strains, vancomycin- and/or linezolid-resistant enterococci, and methicillin-resistant Staphylococcus aureus (MRSA). Tigecycline showed excellent activity against a collection of difficult-to-treat pathogens currently encountered in the hospital setting.
No takes yet. Share an insight, caveat, or question.
Souli et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: